Opinion Article by Brian Murray, Director, Orion Health.
The NHS needs help, it's not broken - we all depend upon it. Turn on the radio, open a webpage, and there will be news about ambulances queuing outside hospitals, patients queueing inside A&E, and discharges being delayed, often for weeks.

One of England's integrated care systems proved the benefit of modern, cloud-telephony during the COVID-19 pandemic, and is now working with X-on on new ideas to support GPs and patients, following a roll-out to practices. Associate director of digital & technology Alicia Dunsby explains.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has once again been recognized as a Clarivate Top 100 Global Innovator™ in Clarivate Analytics' 2023 list, which measures excellence focused on consistency and scale in innovativeness [1], thanks to its constant high performance on these metrics. Philips has now been included in this reputable list for 10 consecutive years.

Opinion Article by Dr Alastair Kirby, Industry and Technology Navigator, Kent Surrey Sussex Academic Health Science Network (KSS AHSN)
You've got an innovative and excellent product, so why aren't NHS influencers and decision makers talking about it? Simple answer may be that they don’t know about you, your product or its value. Effective marketing can help you to change this.

Opinion Article by Mark Pridmore, Head of Strategy, CaseCapture.
NHS teams are under pressure. Could modern digital approaches to clinical audit be a quick win to help relieve just some of the burden? Could organisations better understand performance at such busy times? And could compliance with new CQUINs be supported in the process?

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a long-term strategic partnership with TriHealth, a leading Cincinnati-based integrated healthcare delivery system, to adopt Philips' integrated portfolio of cardiology solutions for its new TriHealth Heart & Vascular Institute on the campus of Bethesda North Hospital and the Harold and Eugenia Thomas Comprehensive Care Center.

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).